EKAPARTNERS advised SUBSTIPHARM

Ekapartners is pleased to announce it has advised Substipharm on its syndicated loan financed by LCL, Banque Palatine, Societe Generale Corporate & Investment Banking, Banque Populaire Rives de Paris and Neuflize OBC.

We optimized the terms and conditions for the company while providing it with significant resources to continue to pursue a proactive external growth strategy.
Substipharm is the French leader in the development of generic or niche pharmaceutical products. The Group is specialized in supplying medicines to pharmaceutical companies that market them in more than 50 countries in Europe and internationally.

Since 2017, Substipharm also directly operates medicines either acquired from pharmaceutical groups or from its own development pipeline.